Active, not recruitingPhase 2NCT02314169
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Cathy Eng, M.DYale University Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 143 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2026
Study locations (30)
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States
- Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States
- Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
- Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States
- Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02314169 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital